Certara (NASDAQ:CERT) Reaches New 1-Year Low Following Analyst Downgrade

Certara, Inc. (NASDAQ:CERT)’s stock price hit a new 52-week low during mid-day trading on Saturday after Barclays lowered their price target on the stock from $16.00 to $14.00. Barclays currently has an overweight rating on the stock. Certara traded as low as $8.47 and last traded at $8.67, with a volume of 9104388 shares trading hands. The stock had previously closed at $11.27.

Several other equities analysts also recently weighed in on CERT. Craig Hallum initiated coverage on shares of Certara in a research note on Monday, September 29th. They issued a “buy” rating and a $16.00 target price for the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Certara in a report on Wednesday, October 8th. KeyCorp boosted their target price on shares of Certara from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, October 8th. Zacks Research upgraded Certara from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Finally, UBS Group reduced their price target on Certara from $17.50 to $15.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $15.38.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total value of $559,366.08. Following the transaction, the insider directly owned 73,979 shares in the company, valued at $807,850.68. This represents a 40.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.33% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Certara

A number of institutional investors and hedge funds have recently bought and sold shares of CERT. AdvisorNet Financial Inc purchased a new position in Certara in the 2nd quarter worth approximately $25,000. First Horizon Corp bought a new stake in shares of Certara during the 3rd quarter worth $30,000. Caitong International Asset Management Co. Ltd purchased a new position in Certara in the first quarter worth $31,000. Versant Capital Management Inc increased its stake in Certara by 66.7% in the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after acquiring an additional 1,153 shares during the last quarter. Finally, AlphaQuest LLC purchased a new stake in Certara during the first quarter valued at about $39,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Stock Down 23.1%

The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 0.27. The stock has a 50-day simple moving average of $11.77 and a two-hundred day simple moving average of $11.51. The firm has a market cap of $1.39 billion, a PE ratio of 123.86 and a beta of 1.44.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.11 by $0.03. The firm had revenue of $104.62 million for the quarter, compared to analyst estimates of $104.53 million. Certara had a return on equity of 5.17% and a net margin of 2.62%.During the same period in the prior year, the company earned $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. Analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.